InsiderTrades

Form 4 for HQ Horizon Quantum Holdings Ltd.

Accepted 2026-09-15 21:30:10 ET · period of report 2026-06-12 · accession 0001213900-26-100279 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-09-15 21:30 2026-09-12 HQ Fitzsimons Joseph Francis CEO, Dir, 10% M - OptEx $0.00 +14.3K 14.3K New $0
D 2026-09-15 21:30 2026-09-12 HQ Fitzsimons Joseph Francis CEO, Dir, 10% D - Sale to Iss $15.22 -3,438 10.9K -24% -$52.3K
D 2026-09-15 21:30 2026-06-12 HQ Fitzsimons Joseph Francis CEO, Dir, 10% A - Grant $0.00 +229.1K 229.1K New $0
D 2026-09-15 21:30 2026-09-12 HQ Fitzsimons Joseph Francis CEO, Dir, 10% M - OptEx $0.00 +14.3K 214.8K +7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Shares 2026-09-12 M A 14,321 $0.00 14,321 D — — (F1) On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. (F1) On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date.
2 Common Class A Ordinary Shares 2026-09-12 D D 3,438 $15.22 10,883 D — — (F1) On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. (F3) The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026. (F3) The reported disposition to the Company reflects the settlement in cash of a portion of the RSUs which vested on September 12, 2026, at a price per ordinary share of $15.22, the last reported sales price of the Company's Class A Ordinary Shares on September 11, 2026.
3 Derivative Restricted Stock Unit 2026-06-12 A A 229,148 $0.00 229,148 D $0.00 · — to — 229,148 Class A Ordinary Shares (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date.
4 Derivative Restricted Stock Unit 2026-09-12 M A 14,321 $0.00 214,827 D $0.00 · — to — 14,321 Class A Ordinary Shares (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. (F1) On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. (F1) On September 12, 2026, 14,321 of Dr. Fitzsimons's RSU's vested. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date. (F2) On June 12, 2026 (the "Grant Date"), Dr. Fitzsimons was granted a total of 229,148 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one Class A ordinary share, with no par value ("Class A Ordinary Share"), of Horizon Quantum Holdings Ltd. (the "Company") upon vesting, for no consideration. The RSUs granted to Dr. Fitzsimons vest in sixteen approximately equal installments on successive quarterly anniversaries of the Grant Date and are subject to Dr. Fitzsimons's continued employment with the Company through each applicable vesting date.